一種記錄和監測腦部電活動新型神經監測系統被設計用于急性監護患者：例如嚴重癲癇接受選擇性外科手術治療的患者，腦卒中和腦損傷接受顱骨切開手術的患者。這套系統已經獲得了美國食品藥品管理局的許可。

這套系統包括NeuroPort腦皮質層微電極檢測（NeuroPort檢測）以及NeuroPort神經信號處理器（NeuroPort NSP）。NeuroPort系統為神經科醫生和神經外科醫生提供了一種檢測、傳播以及分析接受顱骨切開手術患者的神經活動的新方法。這種檢測方法可以從大腦皮質層收集綜合的或者單個的神經信號。NSP可以記錄這些信號，醫生通過分析這些信號，將其做為診斷與治療神經系統疾病的一部分。

研制開發這套系統的Cyberkinetics神經技術系統公司的總裁兼首席執行官Timothy R.Surgenor說：“NeuroPort系統是我們首個商業化的臨床產品，其獲得上市許可，是我們公司開發用于診斷、檢測和治療神經系統疾病和損傷產品戰略極其重要的第一步。NeuroPort檢測和NeuroPort SNP是來自我們BrainGate神經界面系統的重要組成部分。”
 
Neural Monitoring of Acute Care Patients
 
A new neural system that records and monitors brain electrical activity is designed for patients in acute care, such as patients undergoing elective surgery for the treatment of severe epilepsy and patients undergoing emergency craniotomies for stroke and brain injury. The system has been cleared by the U.S. Food and Drug Administration (FDA).

The system comprises the NeuroPort cortical microelectrode array (NeuroPort array) and the NeuroPort neural signal processor (NeuroPort NSP). The NeuroPort system provides neurologists and neurosurgeons with a new resource to detect, transmit, and analyze neural activity of patients who have undergone craniotomy. The array allows the collection of aggregate or individual neural signals from the cortical region of the brain. The NSP allows these signals to be recorded and analyzed by the doctor as a part of the diagnosis and treatment of neurologic conditions.

“Marketing clearance of the NeuroPort system, our first commercial clinical product, is an important first step in our strategy to develop a broad family of products to diagnose, monitor, and treat neurological diseases and injuries,” noted Timothy R. Surgenor, president and CEO of Cyberkinetics Neurotechnology Systems, Inc. (Foxborough, MA, USA), which developed the system. “The NeuroPort array and the NeuroPort SNP are both critical components derived from our BrainGate neural interface system.”